For the year ending 2025-12-31, RLMD had -$360,486 decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -57,385,163 |
| Stock-based compensation | 13,905,181 |
| Stock appreciation rights compensation | 1,056,464 |
| Issuance of restricted common stock | 905,226 |
| Realized (gain) loss on short-term investments | -79,207 |
| Unrealized gain on short-term investments | 398,255 |
| Prepaid expenses and other assets | 88,785 |
| Accounts payable | -2,561,619 |
| Accrued expenses | -1,299,244 |
| Net cash used in operating activities | -45,786,988 |
| Purchase of short-term investments | 83,828,576 |
| Sale of short-term investments | 35,690,270 |
| Net cash (used in)/provided by investing activities | -48,138,306 |
| Proceeds from issuance of common stock, net | 93,637,829 |
| Payment of atm fees | 73,021 |
| Net cash provided by/(used in) financing activities | 93,564,808 |
| Net decrease in cash and cash equivalents | -360,486 |
| Cash and cash equivalents at beginning of the year | 3,857,026 |
| Cash and cash equivalents at end of the year | 3,496,540 |
RELMADA THERAPEUTICS, INC. (RLMD)
RELMADA THERAPEUTICS, INC. (RLMD)